Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyAvMed Cinqair (reslizumab) Prior Auth Coverage | O…
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Cinqair (reslizumab) IV — Prior Authorization Coverage Criteria

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria and administrative requirements for AvMed coverage of Cinqair (reslizumab) intravenous therapy for members, including initial and reauthorization clinical criteria and documentation requirements; applies to providers requesting medical benefit coverage for the drug.

    Policy Summary
    PayerAvMed
    PolicyCinqair (reslizumab) IV — Prior Authorization Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJun 15, 2022
    Next Review DateN/A
    Key ActionSubmit a completed medical prior authorization form with prescriber signature and supporting documentation including baseline peripheral blood eosinophil level and relevant chart notes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum age
    >400Eosinophil threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 mo
    Initial auth duration
    3 mg/kg q4wDose/interval
    Not permittedConcomitant biologics

    Coverage Criteria for Cinqair (reslizumab)

    Initial Authorization

    Covered when ALL of the following are met for initial authorization:

    prescriber: Prescribed by or in consultation with an allergist, immunologist or pulmonologist
    age: Member is 18 years of age or older>=18 years
    eosinophils: Baseline (pre-Cinqair) peripheral blood eosinophil level of > 400 cells/microliter>400 cells/microliter

    Submit labs collected within the past 12 months

    controller_trial: Member is currently being treated with ONE of the following unless there is a contraindication or intolerance and must be compliant on therapy for at least 90 consecutive days within a year of request: (a) high-dose inhaled corticosteroid AND an additional asthma controller OR (b) one maximally dosed combination ICS/LABA product90 days

    Trials will be verified via pharmacy claims/chart notes

    exacerbation_history: Member has experienced ONE of: more than 2 exacerbations requiring additional medical treatment in the past 12 months OR any prior intubation for an asthma exacerbation OR baseline FEV1 < 80% predicted submitted within year of request

    Reauthorization

    Covered when ALL of the following are met for reauthorization:

    clinical_response: Member has experienced a sustained positive clinical response to Cinqair as demonstrated by at least ONE of: increase in percent predicted FEV1 from baseline, reduction in dose of inhaled corticosteroids required, reduction in use of oral corticosteroids, reduction in asthma symptoms (chest tightness, coughing, shortness of breath, nocturnal awakenings)

    Chart notes must be submitted

    ongoing_controller: Member is currently being treated with ONE of the following unless there is a contraindication or intolerance: (a) high-dose inhaled corticosteroid AND an additional asthma controller OR (b) one maximally dosed combination ICS/LABA product

    AvMed considers concomitant therapy of Cinqair (reslizumab) with other listed biologic agents to be experimental/investigational. Safety and efficacy of combining Cinqair with these agents have not been established, and such combinations will not be permitted.

    Specifically, use of Cinqair in combination with Dupixent, Fasenra, Nucala, Tezspire, or Xolair is considered investigational and is not covered. If a member has an active authorization for any of these agents on file, subsequent requests for Cinqair will not be approved.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J2786Cinqair (reslizumab) injection
    Baseline peripheral blood eosinophil count
    Baseline eosinophil threshold> 400 cells/microliter (baseline pre‑Cinqair peripheral blood eosinophil level)
    Timing of labSubmit labs collected within the past 12 months
    Failing controller definitionA failure after trial of at least 90 consecutive days of high‑dose ICS plus LABA is defined as blood eosinophil count > 400 cells/microliter
    Minimum age requirement
    Minimum age18 years or older
    DocumentationMember age must be documented on the request form

    Provider Requirements and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required — Cinqair (reslizumab) IV requires prior authorization before administration. Submit the completed Medical Prior Authorization/Step-Edit Request form (prescribing physician signature required) and fax to 1-877-535-1391. Incomplete, incorrect, or illegible requests may delay processing or result in denial.

    • Prescribing physician must sign and clearly print name (preprinted stamps not valid).
    • For Medicare members, comply with applicable NCDs/LCDs per CMS. See Medicare Coverage Database.
    Denial Risk

    Concurrent Biologic Therapy — Not Permitted

    Concurrent biologic therapy is not permitted. AvMed considers concomitant use of Cinqair with Dupixent, Fasenra, Nucala, Tezspire, or Xolair to be experimental/investigational; safety and efficacy have not been established. If the member has an active authorization for Dupixent®, Fasenra®, Nucala®, Tezspire™ or Xolair®, any request for Cinqair® will NOT be approved.

    Background

    Cinqair (reslizumab) is an intravenous monoclonal antibody indicated for severe eosinophilic asthma and is administered by infusion. The policy notes the recommended dosage as 3 mg/kg once every 4 weeks by intravenous infusion over 20–50 minutes, and establishes clinical and administrative requirements for prior authorization and use within AvMed.

    Key Definitions

    Severe eosinophilic phenotype
    DefinitionSevere eosinophilic phenotype: baseline (pre‑Cinqair) peripheral blood eosinophil level > 400 cells/microliter
    Lab recencyEosinophil level must be from within the past 12 months
    Use in criteriaA blood eosinophil count > 400 cells/µL is required for initial authorization
    Recommended dosage
    Recommended dosing3 mg/kg once every 4 weeks by intravenous infusion over 20–50 minutes
    Administration timeInfuse over 20–50 minutes
    Record keeping
    Policy Summary
    PayerAvMed
    PolicyCinqair (reslizumab) IV — Prior Authorization Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJun 15, 2022
    Next Review DateN/A
    Key ActionSubmit a completed medical prior authorization form with prescriber signature and supporting documentation including baseline peripheral blood eosinophil level and relevant chart notes.
    SourceLink
    On This Page
    Coverage Criteria for Cinqair (reslizumab)Billing and CodingProvider Requirements and DocumentationBackgroundKey Definitions
    Prescriber requirement
    Prescribed by or in consultation with an allergist, immunologist, or pulmonologist
    Recommended dose
    Recommended dose and interval3 mg/kg once every 4 weeks by intravenous infusion
    Infusion frequencyEvery 4 weeks (q4w)
    Weight‑based dosingDose calculated on patient weight (mg/kg); record weight and date obtained
    • Requests will be denied when an active authorization for any listed biologic is on file.
    Documentation Required

    Required Supporting Documentation

    Required supporting documentation must be submitted for each checked clinical criterion. Provide chart notes, relevant diagnostics, and lab results to support diagnosis, prior therapy trials, baseline and follow-up measurements, and observed clinical response. Trials may be verified via pharmacy claims and/or submitted chart notes; lack of documentation may result in denial.

    • Documentation to include: clinical progress notes, allergy/immunology or pulmonology consultation notes, and medication history (including dates and doses).
    • Baseline peripheral blood eosinophil count (pre-Cinqair) with date — labs must be within the past 12 months.
    • Baseline and follow-up pulmonary function testing showing FEV1 percent predicted (submit most recent within past 12 months).
    • Evidence of trial and failure or contraindication/intolerance to required controller therapies with dates — member must have been compliant for at least 90 consecutive days within the year prior to request.
    • Evidence of exacerbation history (e.g., ED visits, hospitalizations, intubation, oral corticosteroid bursts) if claimed.
    • For continuation requests, documentation of sustained positive clinical response (e.g., increased FEV1, reduced inhaled/oral corticosteroid dose, reduced symptoms) with supporting chart notes.
    Documentation Required

    Required Baseline Labs and Pulmonary Function Data

    Baseline labs and pulmonary function data required: submit a pre-treatment peripheral blood eosinophil count showing > 400 cells/µL (collect after a trial and failure of at least 90 consecutive days of high‑dose ICS + LABA; labs must be within the past 12 months). Submit baseline FEV1 percent predicted documented within the past 12 months showing < 80% predicted if claimed.

    • Eosinophil count value and date of draw.
    • FEV1 percent predicted value and date of test.
    • Supporting notes documenting timing of controller therapy trial relative to lab draw.
    Denial Risk

    Incomplete/Incorrect Request Risk

    Incomplete requests increase risk of delay or denial. Ensure all fields on the authorization form are complete, legible, and include provider contact information. The prescribing physician signature is required; preprinted stamps are not valid.

    • Fax completed form to 1-877-535-1391.
    • Include phone and fax numbers to avoid follow-up delays.
    Step Therapy

    Required Controller Therapy Trial

    Required controller therapy trial — member must have trial and failure or documented contraindication/intolerance to specified controller therapies. Trial must show at least 90 consecutive days of compliance within the year prior to request.

    • Acceptable evidence: medication refill history, pharmacy claims, and chart notes documenting dates and adherence for a minimum 90-day consecutive period.
    • Specify whether trial was: high‑dose ICS + additional controller, or maximally dosed ICS/LABA product, and include doses.
    • If contraindication/intolerance is claimed, provide supporting clinical documentation.
    Document infusion dosing, duration, and patient weight on authorization form